The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles
Open accessAbstract
Purpose Allergen-specific immunotherapy (SIT) requires dozens of subcutaneous injections over 3 to 5 years in order to control IgE-mediated hypersensitivity, which is a T-helper 2 (Th2)-associated pathology. This study investigates the use of poly(lactide-co-glycolide) (PLGA) microparticles combined with immunostimulatory oligodeoxynucleotide (CpG), as well as protamine in SIT.Materials and methods We prepared microparticle formulations with the major allergen of bee venom, phospholipase A2 (PLA2), and analyzed the effect of co-encapsulated or admixed CpG in both naïve and bee venom allergic mice.Results Mice immunized with microparticles containing only PLA2 induced weak antibody responses. In contrast, the combination with CpG resulted in strong PLA2-specific antibody responses. The presence of CpG was required for the induction of the Th1-associated isotype IgG2a, and the titers of IgG2a in sensitized mice correlated with a better protection against an allergen challenge. The effect of CpG was further strengthened when protamine was co-encapsulated for complexation of CpG.Conclusions This study shows that allergen-specific immunotherapy with a PLGA-based allergen-delivery system in combination with CpG enhanced the induction of protective IgG2a immune responses. This may improve SIT compliance and shorten its duration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“recent data indicated the counterbalance of Th2 responses by the use of PLGA particles co-encapsulated with the immuno stimulatory TLR9 ligand oligodeoxy-nucleotide (CpG), protamine and phospholipase A2 from bee venom [123].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [123]
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paper
Bousquet, J., Lockey, R., & Malling, H.-J. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70271-4 · Cited by 1,581
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
Durham, S. R., Walker, S. M., Varga, E.-M., Jacobson, M. R., O'Brien, F., Noble, W., Till, S. J., Hamid, Q. A., & Nouri-Aria, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410702 · Cited by 1,373
Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases
Bousquet, J., Lockey, R., Malling, H. J., Alvarez-Cuesta, E., Canonica, G. W., Chapman, M. D., Creticos, P. J., Dayer, J. M., Durham, S. R., Demoly, P., et al. (1998) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63136-5 · Cited by 736
Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity
Nouri-Aria, K. T., Wachholz, P. A., Francis, J. N., Jacobson, M. R., Walker, S. M., Wilcock, L. K., Staple, S. Q., Aalberse, R. C., Till, S. J., & Durham, S. R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3252 · Cited by 564
Immunotherapy with a Ragweed–Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis
Creticos, P. S., Schroeder, J. T., Hamilton, R. G., Balcer-Whaley, S. L., Khattignavong, A. P., Lindblad, R., Li, H., Coffman, R., Seyfert, V., Eiden, J. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052916 · Cited by 562
Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.
Secrist, H., Chelen, C. J., Wen, Y., Marshall, J. D., & Umetsu, D. T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2123 · Cited by 539
Cited by
mRNA vaccination as a safe approach for specific protection from type I allergy
Weiss, R., Scheiblhofer, S., Roesler, E., Weinberger, E., & Thalhamer, J. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.168 · Cited by 42
Use of lectin-functionalized particles for oral immunotherapy
Diesner, S. C., Wang, X.-Y., Jensen-Jarolim, E., Untersmayr, E., & Gabor, F. (2012) · Therapeutic Delivery · doi:10.4155/tde.11.146 · Cited by 40
Metadata
- Authors
- Gómez, J. M. M., Fischer, S., Csaba, N., Kündig, T. M., Merkle, H. P., Gander, B., & Johansen, P.
- Affiliations
- University Hospital Zurich (CH)
- ETH Zurich (CH)
- Corresponding author
- Johansen, Pål
- Venue
- Pharmaceutical Research
- Published
- 2007-05-31
- Volume
- 24
- Issue
- 10
- Pages
- 1927-1935
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2045281155
- Cited by
- 63
- References
- 44
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 4 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 6 · 2014: 5 · 2013: 5 · 2012: 4
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.zora.uzh.ch
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- ETH Zürich Research Collection
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- allergen immunotherapy, allergy vaccines, PLGA microspheres, CpG oligodeoxynucleotides, protamine, bee venom allergy, phospholipase A2, IgG2a, Th1 response, IgE-mediated hypersensitivity
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Adjuvants, Immunologic, Allergens, Anaphylaxis, Animals, Bee Venoms, Chemistry, Pharmaceutical, Desensitization, Immunologic, Disease Models, Animal, Drug Carriers, Drug Compounding, Hypersensitivity, Immunoglobulin E, Immunoglobulin G, Injections, Subcutaneous, Oligodeoxyribonucleotides, Particle Size, Polyglycolic Acid, Polymers, Protamines, Time Factors, Vaccines, Th1 Cells, Lactic Acid, Mice, Phospholipases A2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles. https://app.cochat.ai/papers/10.1007/s11095-007-9318-0
- The paper
- Gómez, J. M. M., Fischer, S., Csaba, N., Kündig, T. M., Merkle, H. P., Gander, B., & Johansen, P. (2007). A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles. Pharmaceutical Research. https://doi.org/10.1007/s11095-007-9318-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.